Author(s):
Sai Samadhan Shirsath, Vaishanavi Samadhan Shirsath, Rahul Tanaji Bhopale
Email(s):
saishirsath06@gmail.com
DOI:
10.52711/2349-2988.2024.00024 
Address:
Sai Samadhan Shirsath1, Vaishanavi Samadhan Shirsath2, Rahul Tanaji Bhopale3
1 Matoshri Institute of Pharmacy Dhanore, Tal Yeola, Dist.: Nashik.
2SND Babhulgaon, Tal: Yeola, Dist.: Nashik.
3Yashwant Redekar College of Pharmacy At: Nesari.
*Corresponding Author
Published In:
Volume - 16,
Issue - 2,
Year - 2024
ABSTRACT:
Naegleria fowleri, colloquially termed the "brain-eating amoeba," presents a formidable public health concern due to its astonishingly high fatality rate of 98%. This abstract provides a thorough examination of the various aspects surrounding Naegleria fowleri, encompassing its morphology, life cycle, transmission routes, clinical manifestations, diagnostic methods, treatment strategies, and preventive measures. Naegleria fowleri, an amoeboid protist, thrives in warm freshwater environments, predominantly in regions with elevated temperatures. Infections occur when contaminated water enters the nasal passages, leading to primary amebic meningoencephalitis (PAM), an acute and often fatal condition affecting the central nervous system. The clinical course of PAM is rapid, with symptoms escalating from initial flu-like manifestations to severe neurological impairment within days. Diagnosis of PAM remains challenging, relying on specialized laboratory techniques such as polymerase chain reaction (PCR) and immunofluorescence assays. Despite efforts to develop effective treatments, mortality rates remain alarmingly high, emphasizing the critical importance of preventive measures. Avoiding freshwater activities in warm, stagnant water bodies, utilizing nose clips or plugs during water-related activities, and ensuring proper disinfection of recreational water sources are key strategies in mitigating the risk of the risk of Naegleria fowleri infections and reducing its devastating impact on public health.
Cite this article:
Sai Samadhan Shirsath, Vaishanavi Samadhan Shirsath, Rahul Tanaji Bhopale. Naegleria fowleri 98 Percent Fatal a Comprehensive Survey. Research Journal of Science and Technology. 2024; 16(2):163-8. doi: 10.52711/2349-2988.2024.00024
Cite(Electronic):
Sai Samadhan Shirsath, Vaishanavi Samadhan Shirsath, Rahul Tanaji Bhopale. Naegleria fowleri 98 Percent Fatal a Comprehensive Survey. Research Journal of Science and Technology. 2024; 16(2):163-8. doi: 10.52711/2349-2988.2024.00024 Available on: https://rjstonline.com/AbstractView.aspx?PID=2024-16-2-9
REFRENCES:
1. Marciano-Cabral F, Cabral G. The immune response to Naegleria fowleri amebae and pathogenesis of infection. FEMS Immunol Med Microbiol. 2007; 51: 243-59.
2. Visvesvara GS. Free-living amebae as opportunistic agents of human disease. J Neuroparasitol. 2010; 1.
3. Yoder JS, Eddy BA, Visvesvara GS, Capewell L, Beach MJ. "The epidemiology of primary amoebic meningoencephalitis in the USA, 1962-2008. Epidemiol Infect. 2010; 138: 968-75.
4. Capewell LG, Harris AM, Yoder JS, Cope JR, Eddy BA, Roy SL, Visvesvara GS, Fox LM, Beach MJ. Diagnosis, clinical course, and treatment of primary amoebic meningoencephalitis in the United States, 1937–2013. J Pediatric Infect Dis Soc. 2014; Epub: 1–8.
5. Seidel J, Harmatz P, Visvesvara GS, Cohen A, Edwards J, Turner J. Successful treatment of primary amebic meningoencephalitis. New Engl J Med. 1982; 306: 346-8.
6. Vargas-Zepeda J, Gomez-Alcala AV, Vasquez-Morales JA, Licea-Amaya L, De Jonckheere JF, Lores-Villa F. Successful treatment of Naegleria PAM using IV amphotericin B, fluconazole, and rifampin. Arch Med Res. 2005; 36: 83-6.
7. Linam WM, Ahmed M, Cope JR, Chu C, Visvesvara GS, da Silva AJ, Qvarnstrom Y, Green J. Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis. Pediatrics. 2015; 135: e744-748.
8. Cope JR, Conrad DA, Cohen N, Cotilla M, DaSilva A, Jackson J, Visvesvara GS. Use of the novel therapeutic agent miltefosine for the treatment of primary amebic meningoencephalitis: report of 1 fatal and 1 surviving case. Clin Infect Dis. 2016;62(6):774-6.
9. John DT, John RA. Cytopathogenicity of Naegleria fowleri in mammalian cell cultures. Parasitol Res. 1989;76:20-5.
10. N. R. Pan and T. N. Ghosh. Primary amoebic meningoencephalitis in two Indian children. Journal of the Indian Medical Association, 1971; 56(5): 134–137.
11. S. N. Singh, A. K. Patwari, R. Dutta, N. Taneja, and V. K. Anand. Naegleria meningitis. Indian Pediatrics. 1998; 35(10); 1012–1015.
12. S. Shenoy, G. Wilson, H. V. Prashanth, K. Vidyalakshmi, B. Dhanashree, and R. Bharath. Primary meningoencephalitis by Naegleria fowleri: first reported case from Mangalore, South India. Journal of Clinical Microbiology. 2002; 40(1): 309–310.
13. R. Jain, S. Prabhakar, M. Modi, R. Bhatia, and R. Sehgal. Naegleria meningitis: a rare survival, Neurology India. 2002; 50(4): 470–472.
14. S. Hebbar, I. Bairy, N. Bhaskaranand, S. Upadhyaya, M. S. Sarma, and A. K. Shetty, Fatal case of Naegleria fowleri meningo-encephalitis in an infant: case report. Annals of Tropical Paediatrics. 2005; 25(3): 223–226.
15. Hahn HJ, Debnath A. In vitro evaluation of farnesyltransferase inhibitor and its effect in combination with 3-hydroxy-3-methyl- glutaryl-CoA reductase inhibitor against Naegleria fowleri. Pathogens. 2020; 9(9): 689.
16. Hahn HJ, Abagyan R, Podust LM, et al. HMG-CoA reductase inhibitors as drug leads against Naegleria fowleri. ACS Chem Neurosci. 2020; 11(19): 3089–30.
17. Rizo-Liendo A, Sifaoui I, Reyes-Batlle M, et al. In vitro activity of statins against Naegleria fowleri. Pathogens. 2019; 8(3): 122.
18. Sarink MJ, Tielens AGM, Verbon A, et al. Inhibition of Fatty Acid Oxidation as a New Target To Treat Primary Amoebic Meningoencephalitis. Antimicrob Agents Chemother. 2020; 64(8).